Radiopharmaceuticals Market Size, Share, and Trends 2024 to 2034

The global radiopharmaceuticals market size is calculated at USD 7.51 billion in 2025 and is forecasted to reach around USD 14.44 billion by 2034, accelerating at a CAGR of 7.53% from 2025 to 2034. The North America market size surpassed USD 2.96 billion in 2024 and is expanding at a CAGR of 7.49% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : March 2025
  • Report Code : 3418
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Radiopharmaceuticals Market 

5.1. COVID-19 Landscape: Radiopharmaceuticals Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Radiopharmaceuticals Market, By Radioisotope

8.1. Radiopharmaceuticals Market, by Radioisotope

8.1.1. Iodine I

8.1.1.1. Market Revenue and Forecast

8.1.2. Gallium 68

8.1.2.1. Market Revenue and Forecast

8.1.3. Technetium 99m

8.1.3.1. Market Revenue and Forecast

8.1.4. Fluorine 18

8.1.4.1. Market Revenue and Forecast

8.1.5. Others

8.1.5.1. Market Revenue and Forecast

Chapter 9. Global Radiopharmaceuticals Market, By Application

9.1. Radiopharmaceuticals Market, by Application

9.1.1. Cancer

9.1.1.1. Market Revenue and Forecast

9.1.2. Cardiology

9.1.2.1. Market Revenue and Forecast

9.1.3. Others

9.1.3.1. Market Revenue and Forecast

Chapter 10. Global Radiopharmaceuticals Market, By Type 

10.1. Radiopharmaceuticals Market, by Type

10.1.1. Diagnostic

10.1.1.1. Market Revenue and Forecast

10.1.2. Therapeutic

10.1.2.1. Market Revenue and Forecast

Chapter 11. Global Radiopharmaceuticals Market, By End User 

11.1. Radiopharmaceuticals Market, by End User

11.1.1. Hospitals and clinics

11.1.1.1. Market Revenue and Forecast

11.1.2. Medical Imaging centers

11.1.2.1. Market Revenue and Forecast

11.1.3. Others

11.1.3.1. Market Revenue and Forecast

Chapter 12. Global Radiopharmaceuticals Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Radioisotope

12.1.2. Market Revenue and Forecast, by Application

12.1.3. Market Revenue and Forecast, by Type

12.1.4. Market Revenue and Forecast, by End User

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Radioisotope

12.1.5.2. Market Revenue and Forecast, by Application

12.1.5.3. Market Revenue and Forecast, by Type

12.1.5.4. Market Revenue and Forecast, by End User

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Radioisotope

12.1.6.2. Market Revenue and Forecast, by Application

12.1.6.3. Market Revenue and Forecast, by Type

12.1.6.4. Market Revenue and Forecast, by End User

12.2. Europe

12.2.1. Market Revenue and Forecast, by Radioisotope

12.2.2. Market Revenue and Forecast, by Application

12.2.3. Market Revenue and Forecast, by Type

12.2.4. Market Revenue and Forecast, by End User

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Radioisotope

12.2.5.2. Market Revenue and Forecast, by Application

12.2.5.3. Market Revenue and Forecast, by Type

12.2.5.4. Market Revenue and Forecast, by End User

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Radioisotope

12.2.6.2. Market Revenue and Forecast, by Application

12.2.6.3. Market Revenue and Forecast, by Type

12.2.6.4. Market Revenue and Forecast, by End User

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Radioisotope

12.2.7.2. Market Revenue and Forecast, by Application

12.2.7.3. Market Revenue and Forecast, by Type

12.2.7.4. Market Revenue and Forecast, by End User

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Radioisotope

12.2.8.2. Market Revenue and Forecast, by Application

12.2.8.3. Market Revenue and Forecast, by Type

12.2.8.4. Market Revenue and Forecast, by End User

12.3. APAC

12.3.1. Market Revenue and Forecast, by Radioisotope

12.3.2. Market Revenue and Forecast, by Application

12.3.3. Market Revenue and Forecast, by Type

12.3.4. Market Revenue and Forecast, by End User

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Radioisotope

12.3.5.2. Market Revenue and Forecast, by Application

12.3.5.3. Market Revenue and Forecast, by Type

12.3.5.4. Market Revenue and Forecast, by End User

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Radioisotope

12.3.6.2. Market Revenue and Forecast, by Application

12.3.6.3. Market Revenue and Forecast, by Type

12.3.6.4. Market Revenue and Forecast, by End User

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Radioisotope

12.3.7.2. Market Revenue and Forecast, by Application

12.3.7.3. Market Revenue and Forecast, by Type

12.3.7.4. Market Revenue and Forecast, by End User

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Radioisotope

12.3.8.2. Market Revenue and Forecast, by Application

12.3.8.3. Market Revenue and Forecast, by Type

12.3.8.4. Market Revenue and Forecast, by End User

12.4. MEA

12.4.1. Market Revenue and Forecast, by Radioisotope

12.4.2. Market Revenue and Forecast, by Application

12.4.3. Market Revenue and Forecast, by Type

12.4.4. Market Revenue and Forecast, by End User

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Radioisotope

12.4.5.2. Market Revenue and Forecast, by Application

12.4.5.3. Market Revenue and Forecast, by Type

12.4.5.4. Market Revenue and Forecast, by End User

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Radioisotope

12.4.6.2. Market Revenue and Forecast, by Application

12.4.6.3. Market Revenue and Forecast, by Type

12.4.6.4. Market Revenue and Forecast, by End User

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Radioisotope

12.4.7.2. Market Revenue and Forecast, by Application

12.4.7.3. Market Revenue and Forecast, by Type

12.4.7.4. Market Revenue and Forecast, by End User

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Radioisotope

12.4.8.2. Market Revenue and Forecast, by Application

12.4.8.3. Market Revenue and Forecast, by Type

12.4.8.4. Market Revenue and Forecast, by End User

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Radioisotope

12.5.2. Market Revenue and Forecast, by Application

12.5.3. Market Revenue and Forecast, by Type

12.5.4. Market Revenue and Forecast, by End User

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Radioisotope

12.5.5.2. Market Revenue and Forecast, by Application

12.5.5.3. Market Revenue and Forecast, by Type

12.5.5.4. Market Revenue and Forecast, by End User

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Radioisotope

12.5.6.2. Market Revenue and Forecast, by Application

12.5.6.3. Market Revenue and Forecast, by Type

12.5.6.4. Market Revenue and Forecast, by End User

Chapter 13. Company Profiles

13.1. Bayer AG

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Iso-Tex Diagnostics, Inc

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Jubilant Pharmova Limited

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Novartis AG

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. General Electric Company

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Lantheus Holdings, Inc

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Eli Lilly and Company

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Siemens AG

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Curium Pharma

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Cardinal Health Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global radiopharmaceuticals market size is expected to increase USD 14.44 billion by 2034 from USD 6.74 billion in 2024.

The global radiopharmaceuticals market will register growth rate of 7.53% between 2025 and 2034.

The major players operating in the radiopharmaceuticals market are Bayer AG, Iso-Tex Diagnostics, Inc, Jubilant Pharmova Limited, Novartis AG, General Electric Company, Lantheus Holdings, Inc., Eli Lilly and Company, Siemens AG, Curium Pharma, Cardinal Health Inc., and Others.

The driving factors of the radiopharmaceuticals market are the personalized medicine stands as a distinctive driving force propelling the dynamic expansionof the market and surge in research and development.

North America region will lead the global radiopharmaceuticals market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client